heated humidified high flow nasal cannula oxygen therapy, HFNC: HFNC can accurately provide 21% \~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
Nasal cannula oxygen: Nasal cannula oxygen has become a routine part of postoperative treatment
Study summary
Patients at high risk of post-operative pulmonary complications (PPC) will be screened out from gynecological tumor patients undergoing surgical treatment, and randomly assigned into the HFNC group and control group, which uses conventional nasal cannula oxygen therapy. The primary outcome is the incidence of PPC, including postoperative hypoxemia, atelectasis, pneumonia, etc. Secondary outcomes are the improvement of postoperative oxygenation, antibiotic use, length of hospital stay, adverse events related to oxygen therapy, etc.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients with gynecologic Neoplasms, including benign gynecologic tumors and malignant gynecologic tumors, who are 18 to 90 years old and are scheduled for surgical treatment in our center shall receive plain chest CT scan within 1 week before surgery, and the estimated surgical time shall be ≥2 hours, and at least one of the following conditions shall be met:
1. Assess respiratory risk in surgical patients in Catalonia (ARRSPC) ≥45 points;
2. BMI≥30;
3. Moderate to severe asthma;
4. Moderate to severe chronic obstructive pulmonary disease (COPD);
5. Smoking history ≥20 packs/year
Exclusion Criteria:
1. Patients with lung metastasis of malignant tumor or primary lung malignant tumor;
2. previous lung surgery or radiotherapy;
3. the surgery involved segmental bowel resection.
Primary outcome measure(s)
Postoperative pulmonary complication — 7 days after the surgery The primary outcome measures were the incidence of PPC in the treatment group and the control group, including the incidence of postoperative hypoxemia, atelectasis, pneumonia, etc.
Trial sites (1)
Facility
City
Region
Status
Sichuan Cancer Hospital and Research Institute
Chengdu
Sichuan
Recruiting
More Sichuan Cancer Hospital and Research Institute trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.